Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Plixorafenib - Daiichi Sankyo Company

Next Previous
X
Search
Drug Profile

Plixorafenib - Daiichi Sankyo Company

Alternative Names: FORE 8394; PLX-8394

Latest Information Update: 30 Sep 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Plexxikon
  • Developer Daiichi Sankyo Company; Fore Biotherapeutics; Plexxikon
  • Class Antineoplastics; Cyclopropanes; Fluorobenzenes; Pyridines; Pyrimidines; Pyrroles; Pyrrolidines; Small molecules; Sulfonamides
  • Mechanism of Action Proto-oncogene protein b-raf inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - CNS cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II CNS cancer; Solid tumours
  • Discontinued Hairy cell leukaemia; Malignant melanoma

Most Recent Events

  • 24 Sep 2024 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins plans a phase I trial for Glioma (Second-line therapy or greater) in USA (PO) (NCT06610682)
  • 12 Jul 2024 Fore Biotherapeutics completes a phase I/II trial in Solid tumours (In adolescents, In adults, In children, In the elderly, Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT02428712)
  • 24 Apr 2024 Fore Biotherapeutics initiates a phase I pharmacokinetics trial (In volunteers) in USA (PO) (NCT06385119)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top